Le Lézard
Classified in: Health
Subjects: LBR, CPG

The agreement in principle between Héma-Québec and its nurses and practical nurses in Québec (affiliated with the CSN) is unanimously ratified


MONTREAL, March 20, 2023 /CNW/ - Héma-Québec is pleased to announce that the agreement in principle reached on March 16 with the Syndicat des infirmières et infirmières auxiliaires d'Héma-Québec (CSN) was ratified today by all members present at the general assembly.

The new six-year collective agreement, expiring on March 31, 2025, addresses the concerns expressed by each party. Among other clauses, this new contract allows Héma-Québec's practical nurses to have the same salary ranges as their colleagues in the health and social services network for all the years stipulated therein. Other improvements include:

"I am pleased that we have all reached an agreement. The past few months have been challenging for all of us, our employees, our management teams and executives. We all care about Héma-Québec's mission, and this new collective agreement allows us to move forward and refocus on what we do best, which is saving lives. I would also like to acknowledge the hard work of the employer and union bargaining committees, and thank our managers and employees. They were able to maintain essential services throughout the negotiation period for the benefit of all Quebecers, which reflects their strong commitment to our mission," said Nathalie Fagnan, President and CEO of Héma-Québec.

Héma-Québec has reached an agreement with eight (8) of the nine (9) union units to renew its collective agreements. Negotiations are still ongoing with practical nurses in Montreal.

SOURCE Héma-Québec


These press releases may also interest you

at 05:05
Sun Nuclear, a Mirion Medical company, will feature new and enhanced solutions for better Quality Management at the ESTRO Annual Meeting, May 3-6, in Glasgow, Scotland. The Sun Nuclear booth (#930) will highlight demonstrations and insights on the...

at 04:32
According to the latest BCC...

at 03:05
In Q1 2024, LEO Pharma delivered a revenue growth of 13% in constant exchange rates (CER). The dermatology portfolio saw accelerated growth in revenue of 16%. The acquisition of TMB-001 to the treatment of congenital ichthyosis added a late-stage...

at 02:22
Hansa Biopharma AB (publ), ("Hansa" or the "Company") (STO: HNSA) today announced that the company's registered share capital and number of shares and votes have increased through the issue of 10,474,740 new ordinary shares on 12 April 2024, whereby...

at 02:20
Vicore Pharma Holding (STO:VICO) Stockholm, May 3 2024- Vicore Pharma Holding AB (STO:VICO) ("Vicore"), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), publishes the interim...

2 mai 2024
The report titled "Muscle Stimulator Market by Technique (Burst Mode Alternating Current, Functional Electrical Stimulation, Interferential), Modality (Handheld, Portable, Table Top), Area, Application, End-User - Global Forecast 2024-2030" is now...



News published on and distributed by: